Alkermes plc - Ordinary Shares (NQ:ALKS)

31.95 +0.04 (+0.13%)

Streaming Delayed Price Updated: 12:23 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	816,380
Open	31.64
Bid (Size)	31.93 (200)
Ask (Size)	31.97 (400)
Prev. Close	31.91
Today's Range	31.48 - 32.13
52wk Range	25.16 - 36.32
Shares Outstanding	166,121,384
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

Today 10:57 EST

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

Today 10:46 EST

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Performance

YTD	+13.1%	+13.1%
1 Month	-4.9%	-4.9%
3 Month	+13.3%	+13.3%
6 Month	+10.2%	+10.2%
1 Year	-10.1%	-10.1%

More News

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

Today 10:38 EST

Via The Motley Fool

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗

November 19, 2025

Via Stocktwits

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Preview: Alkermes's Earnings ↗

October 27, 2025

Via Benzinga

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

Today 10:29 EST

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

Today 10:21 EST

Via The Motley Fool

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

February 12, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

February 11, 2026

From Alkermes plc

Via Business Wire

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

January 06, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 30, 2025

From Alkermes plc

Via Business Wire

Alkermes to Participate in Two Upcoming Investor Conferences

November 25, 2025

From Alkermes plc

Via Business Wire

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗

November 14, 2025

Via Benzinga

Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗

November 14, 2025

Via Investor's Business Daily

Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes ↗

November 14, 2025

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study ↗

November 12, 2025

Via Benzinga

This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗

November 11, 2025

Via Benzinga

ALKERMES PLC (NASDAQ:ALKS) Q3 2025 Earnings Beat Estimates and Drive Stock Surge ↗

October 28, 2025

Via Chartmill

Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups ↗

October 24, 2025

Via Benzinga

Breaking Down Alkermes: 8 Analysts Share Their Views ↗

October 23, 2025

Via Benzinga

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗

October 22, 2025

Via Benzinga

Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition

October 22, 2025

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avadel Pharmaceuticals plc (Nasdaq – AVDL), Middlefield Banc Corp. (Nasdaq – MBCN), Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated

October 22, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?

Yes, Alkermes plc - Ordinary Shares is publicly traded.

What exchange does Alkermes plc - Ordinary Shares trade on?

Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alkermes plc - Ordinary Shares?

The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market

What is the current price of Alkermes plc - Ordinary Shares?

The current price of Alkermes plc - Ordinary Shares is 31.95

When was Alkermes plc - Ordinary Shares last traded?

The last trade of Alkermes plc - Ordinary Shares was at 02/23/26 12:23 PM ET

What is the market capitalization of Alkermes plc - Ordinary Shares?

The market capitalization of Alkermes plc - Ordinary Shares is 5.31B

How many shares of Alkermes plc - Ordinary Shares are outstanding?

Alkermes plc - Ordinary Shares has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.